Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Myeloma: early-phase trial registry
167 of 441 indexed Multiple Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11 of 28,707 conditions by registered trial count.
441 US clinical trials · 167 currently recruiting · #11 of 28,707 conditions by registered trial count
Multiple Myeloma: 441 US clinical trials tracked, 167 recruiting.
Multiple Myeloma is the subject of 441 registered US clinical trials on ClinicalTrials.gov, 167 of them currently open to new participants. 52 are in Phase 3-4 (later-stage) and 298 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 34 of these trials.
Enrollment posture brief
Registry condition multiple-myeloma
OPEN 167 | RECR 38% | LATE 52 | EARLY 298 | RANK #11 | SPON 34
Volume-matched condition peers
Nearest open-share peer: Multiple Sclerosis (38% recruiting · 317 trials)
Multiple Myeloma lists 167 open slots (38% of 441 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Myeloma recruits in line with its size-band peers.
167 of 441 indexed trials (37.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Myeloma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 34 of 441 trials (7.7%). 154 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Myeloma enrolment sits around 65 participants.
Median target enrolment is 65 among the 439 trials that report a genuine target (sentinel values excluded). 262 of those (59.7%) plan for fewer than 100 participants.
-
Multiple Myeloma research is mostly interventional.
386 interventional and 55 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
441 total, page 6 of 9
Ixazomib + Pomalidomide + Dexamethasone In MM
Omar Nadeem, MD
NCT04094961
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Massachusetts General Hospital
NCT02718833
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Weill Medical College of Cornell University
NCT01054196
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Jacob Laubach, MD
NCT04653246
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
NCT03984097
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
NCT04430894
Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation
Emory University
NCT06328699
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
NCT03004287
A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders
Memorial Sloan Kettering Cancer Center
NCT06126341
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
NCT05090566
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Memorial Sloan Kettering Cancer Center
NCT02909036
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Janssen Research & Development
NCT06577025
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT03556332
Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
University of Nebraska
NCT05177536
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
University of Pennsylvania
NCT03549442
Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Wake Forest University Health Sciences
NCT04113018
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
GlaxoSmithKline
NCT04398745
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
NCT05871008
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Beth Israel Deaconess Medical Center
NCT01067287
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Massachusetts General Hospital
NCT01562405
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
NCT04151667
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05823571
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Massachusetts General Hospital
NCT03091257
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
GlaxoSmithKline
NCT07217184
Elimination of Minimal Residual Disease After Transplant
Medical College of Wisconsin
NCT05690984
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
NCT04975555
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
Cullinan Therapeutics
NCT06381141
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
NCT03315026
Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
University of Rochester
NCT04635189
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
NCT03672318
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
GlaxoSmithKline
NCT07217119
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
Memorial Sloan Kettering Cancer Center
NCT04174196
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
GlaxoSmithKline
NCT07150091
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT03070327
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
NCT05767359
Telehealth-based Symptom Management for Veterans Treated With Selinexor
Durham VA Medical Center
NCT06452446
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Memorial Sloan Kettering Cancer Center
NCT05130827
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT04555551
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Hackensack Meridian Health
NCT01297764
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Mayo Clinic
NCT05497804
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Memorial Sloan Kettering Cancer Center
NCT05354557
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT05431608
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
National Cancer Institute (NCI)
NCT04933539
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Janssen Research & Development
NCT06550895
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
Memorial Sloan Kettering Cancer Center
NCT05775094
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
NCT02477878
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Memorial Sloan Kettering Cancer Center
NCT05556798
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
NCT04302324
A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT05139225
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Icahn School of Medicine at Mount Sinai
NCT05560399
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 142 |
| Phase 3 | 45 |
| Phase 4 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Myeloma page
441 registered trials, 167 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 167 Multiple Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Multiple Myeloma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Myeloma condition card totals 441 registered trials; most-linked intervention Dexamethasone; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.